{
    "clinical_study": {
        "@rank": "16464", 
        "acronym": "Phoenix", 
        "arm_group": [
            {
                "arm_group_label": "Phoenix", 
                "arm_group_type": "Experimental", 
                "description": "Application over 29 days twice daily"
            }, 
            {
                "arm_group_label": "Hydrocortison", 
                "arm_group_type": "Active Comparator", 
                "description": "Application over 29 days twice daily"
            }, 
            {
                "arm_group_label": "Untreated skin", 
                "arm_group_type": "No Intervention", 
                "description": "Participants will be observed over 29 days without study treatment"
            }
        ], 
        "brief_summary": {
            "textblock": "The study shall explore whether treatment of atopic dermatitis is equally effective with\n      Phoenix medical device as compared to standard therapy (Hydrocortisone cream)."
        }, 
        "brief_title": "Efficacy/Safety Study to Explore a New Topical Formulation in Atopic Dermatitis", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Dermatitis, Atopic", 
        "condition_browse": {
            "mesh_term": [
                "Dermatitis", 
                "Dermatitis, Atopic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female Caucasians aged between 18 and 60 years\n\n          -  Patients with mild atopic dermatitis (AD) presenting a scoring AD (SCORAD) rating\n             below 50\n\n          -  Skin type I - IV according to Fitzpatrick\n\n          -  Acute AD symptoms on each assessment areas  (local SCORAD \u2265 3 and <= 12) at Baseline\n\n          -  Acute symptom of pruritus at Baseline\n\n        Exclusion Criteria:\n\n          -  Any other skin disease at the test area that would interfere with the clinical\n             assessment in the opinion of the investigator\n\n          -  Moles, tattoos, strong pigmentation, or scars at the test area that would interfere\n             with the clinical assessment\n\n          -  Regular intake of antiphlogistic drugs (for example nonsteroidal anti-inflammatory\n             drugs [NSAIDs])\n\n          -  Any condition or treatment which might influence the trial (e.g. any treatment with\n             topical antibiotics, antifungals, or corticoids) within 14 days prior to screening as\n             well as during the trial (exception: topical treatment of AD lesions other than the\n             test areas (for example, face) with low potency steroids restricted to small areas)\n\n          -  UV-therapy or the use of solarium within 30 days before screening as well as during\n             the trial\n\n          -  Any alternative treatment of AD (e.g. acupuncture, kinesiology, and homoeopathy)\n             within 30 days before screening as well as during the trial"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "0", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 20, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01691209", 
            "org_study_id": "16200", 
            "secondary_id": "2012-001504-38"
        }, 
        "intervention": [
            {
                "arm_group_label": "Phoenix", 
                "description": "Topical formulation applied to the skin", 
                "intervention_name": "Phoenix (BAY81-2996)", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Hydrocortison", 
                "description": "1% Hydrocortison cream applied to the skin", 
                "intervention_name": "1% Hydrocortison cream", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cortisol succinate", 
                "Hydrocortisone acetate", 
                "Hydrocortisone 17-butyrate 21-propionate", 
                "Hydrocortisone", 
                "Hydrocortisone-17-butyrate"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Phoenix", 
            "Hydrocortison", 
            "mild atopic dermatitis", 
            "efficacy", 
            "safety"
        ], 
        "lastchanged_date": "August 9, 2013", 
        "link": [
            {
                "description": "Click here and search for drug information provided by the FDA.", 
                "url": "http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm"
            }, 
            {
                "description": "Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.", 
                "url": "http://www.fda.gov/medwatch/safety.htm"
            }
        ], 
        "location": {
            "facility": {
                "address": {
                    "city": "M\u00fcnster", 
                    "country": "Germany", 
                    "state": "Nordrhein-Westfalen", 
                    "zip": "48155"
                }
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "3", 
        "official_title": "An Investigator-blinded, Randomized, Monocentre, 3-arm, Active Controlled Pilot Trial to Explore the Efficacy and Safety of a Topical Medical Device in Patients With Mild to Moderate Atopic Dermatitis in an Intra-individual Comparison With a Standard Therapy (1% Hydrocortisone Cream) and Untreated Skin", 
        "other_outcome": [
            {
                "measure": "Local scored atopic dermatitis (SCORAD) as clinical assessment by means of the intensity items of the SCORAD index", 
                "safety_issue": "No", 
                "time_frame": "Up to 29 days"
            }, 
            {
                "measure": "Transepidermal water loss (TEWL) as a measure for skin barrier function", 
                "safety_issue": "No", 
                "time_frame": "Up to 29 days"
            }, 
            {
                "measure": "Skin hydration by means of corneometry", 
                "safety_issue": "No", 
                "time_frame": "Up to 29 days"
            }, 
            {
                "measure": "Erythema by means of chromametry", 
                "safety_issue": "No", 
                "time_frame": "Up to 29 days"
            }, 
            {
                "measure": "Intensity of pruritus by means of visual analogue scale (VAS)", 
                "safety_issue": "No", 
                "time_frame": "Up to 29 days"
            }
        ], 
        "overall_official": {
            "affiliation": "Bayer", 
            "last_name": "Bayer Study Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Withdrawn", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01691209"
        }, 
        "responsible_party": {
            "name_title": "Head Medical Affairs", 
            "organization": "Bayer HealthCare AG, Consumer Care"
        }, 
        "secondary_outcome": [
            {
                "description": "Vital signs consist of blood pressure, heart rate and body temperature.", 
                "measure": "Number of participants with abnormal vital signs", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 10 weeks"
            }, 
            {
                "measure": "Number of participants with adverse events as a measure of safety and tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 10 weeks"
            }
        ], 
        "source": "Bayer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bayer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}